Draft guidance from the FDA says menopausal status should not be a basis for exclusion from clinical trials of breast cancer treatments and suggests ways for sponsors to include premenopausal women in studies of hormonal drugs and biological products. The FDA is accepting comments on the guidance.
FDA drafts guidance for breast cancer drug studies
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.